Optimization for Viral Vector Scale Up & Scale Down

In AAV gene therapy manufacturing, speed is everything. Clinical timelines are unforgiving, patients can fall outside dosing windows, and the pressure to advance from early development to GMP production without stumbling at scale is immense. At Andelyn Biosciences, the answer to that pressure isn't to move faster; it's to move more smoothly. This perspective also shapes how we define viral vector scale-up: moving from small, development-scale runs to larger clinical and commercial batches while maintaining product quality, yield, and consistency. In short, viral vector scale-up means translating a well-characterized process across increasing volumes without compromising performance.

‍

"Fast is not always fast," says Andrew Moreo, Head of Process Development and Preclinical Manufacturing at Andelyn. "Smooth is always fast."

‍

That philosophy lies at the heart of what Andelyn calls Optimization-by-Design™, a systematic, data-driven approach to viral vector manufacturing that treats scale-down not as an afterthought but as a direct outcome of getting scale-up right from the start. Viral vector scale-up is challenging because vector-producing cells are sensitive to environmental shifts, shear, oxygen transfer, and nutrient gradients; upstream and downstream unit operations must be tightly controlled; and analytics must confirm comparability across scales. Raw material variability, full-to-empty ratios, and downstream recovery add further complexity.

‍

‍

Building for Scale from Day One

The question of scale must be asked before anything else. That includes: What does viral vector scale-up mean for this program’s dose, indication, and timeline? Which production platform and bioreactor configuration best support it?
"It’s one of the very first questions we ask," Moreo explains. "What scales do we need to be at? And ultimately, what does that scale-down look like at the end of the process?" The answer determines the entire development path and helps teams choose the right production platform for viral vector scale-up by weighing dose needs, serotype behavior, timeline constraints, and facility fit.

‍

DOE: The Engine Behind Optimization

At the center of Andelyn’s Curator® Platform is Design of Experiments (DOE), a multifactorial strategy that evaluates multiple process variables simultaneously rather than one at a time. Upstream, this means exploring cell growth parameters, dissolved oxygen, sparging, and bioreactor power input. Downstream, the same approach optimizes step recoveries across ultracentrifugation and all-column purification. These are among the common methods for scaling up viral vector manufacturing: platformized adherent or suspension processes, DOE-guided parameter definition, scale-down models that reflect large-scale hydrodynamics, and purification trains tuned for target quality attributes.

‍

The payoff is substantial. DOE enables Andelyn’s teams to identify the design space, the parameter combination that maximizes the probability of process success, and to build the process around it. The result is a robust, high-yielding platform in which small-scale runs accurately represent large-scale manufacturing. And productivity is a quality indicator. When a process is highly efficient and high-yielding, downstream concentration steps become less aggressive, resulting in less co-concentration of host-cell DNA and host-cell proteins. High-yield processes also tend to arrive in the downstream with better full-to-empty capsid ratios already established, yielding dividends in both step recoveries and final product quality.

‍

Two Paths, One Framework

Not every program requires the same approach. Andelyn structures its platform around two primary development strategies. For rare diseases, orphan indications, and ocular programs, where patient populations are small and dosing windows can be narrow, the rapid path to GMP is the priority. This approach relies on an adherent platform with standardized parameters and serotype-agnostic ultracentrifugation. Scale-down is simple: it’s just a unit of operation. In one example, Andelyn has taken a program from plasmid to released clinical vector in under six months more than once.

‍

For large-scale programs where yield demands exceed roughly 6×10¹⁵ delivered vector genomes, suspension-based manufacturing with custom optimization is the answer. This pathway takes longer, typically about six months to reach toxicology material, but it enables runs up to 2,000 liters and provides the flexibility to run multiple batches at that scale if needed. Suspension cell cultures play a central role in viral vector scale up by enabling higher volumetric productivity, scalable mixing, and controlled oxygen transfer across bioreactor sizes, helping maintain comparability from development to GMP. They also support choosing the right production platform for viral vector scale up when dose needs and batch numbers are high.

‍

Choosing Platforms and Managing Challenges

How do you choose the right production platform for viral vector scale up? Start with dose and demand forecasting, serotype and producer-cell performance, required timelines, and facility capabilities. Adherent systems can speed early clinical entry with familiar unit ops; suspension systems offer greater scalability and consistency for larger programs. Common methods for scaling up viral vector manufacturing then include parameter scaling (P/V, kLa), single-use bioreactors, optimized transfection or infection strategies, and purification schemes aligned to quality targets.

‍

Scale-Down Is the Destination

What ties both strategies together is the role of the scale-down model. Rather than a retrospective add-on to satisfy a regulatory checkbox, Andelyn treats scale-down as a direct product of a well-executed scale-up. If the process has been properly characterized and optimized at every step, the scale-down model is already in place, providing the foundation for process characterization studies, PPQ batches, and ultimately a BLA filing. In gene therapy, the process is the product. At Andelyn, the process starts with optimization, and a clear, data-driven plan for viral vector scale up.

‍

Experience Andelyn’s Optimization-by-Design Framework

If you're interested in learning more about our design framework and platform process, please contact us.

In AAV gene therapy manufacturing, speed is everything. Clinical timelines are unforgiving, patients can fall outside dosing windows, and the pressure to advance from early development to GMP production without stumbling at scale is immense. At Andelyn Biosciences, the answer to that pressure isn't to move faster; it's to move more smoothly. This perspective also shapes how we define viral vector scale-up: moving from small, development-scale runs to larger clinical and commercial batches while maintaining product quality, yield, and consistency. In short, viral vector scale-up means translating a well-characterized process across increasing volumes without compromising performance.

‍

"Fast is not always fast," says Andrew Moreo, Head of Process Development and Preclinical Manufacturing at Andelyn. "Smooth is always fast."

‍

That philosophy lies at the heart of what Andelyn calls Optimization-by-Design™, a systematic, data-driven approach to viral vector manufacturing that treats scale-down not as an afterthought but as a direct outcome of getting scale-up right from the start. Viral vector scale-up is challenging because vector-producing cells are sensitive to environmental shifts, shear, oxygen transfer, and nutrient gradients; upstream and downstream unit operations must be tightly controlled; and analytics must confirm comparability across scales. Raw material variability, full-to-empty ratios, and downstream recovery add further complexity.

‍

‍

Building for Scale from Day One

The question of scale must be asked before anything else. That includes: What does viral vector scale-up mean for this program’s dose, indication, and timeline? Which production platform and bioreactor configuration best support it?
"It’s one of the very first questions we ask," Moreo explains. "What scales do we need to be at? And ultimately, what does that scale-down look like at the end of the process?" The answer determines the entire development path and helps teams choose the right production platform for viral vector scale-up by weighing dose needs, serotype behavior, timeline constraints, and facility fit.

‍

DOE: The Engine Behind Optimization

At the center of Andelyn’s Curator® Platform is Design of Experiments (DOE), a multifactorial strategy that evaluates multiple process variables simultaneously rather than one at a time. Upstream, this means exploring cell growth parameters, dissolved oxygen, sparging, and bioreactor power input. Downstream, the same approach optimizes step recoveries across ultracentrifugation and all-column purification. These are among the common methods for scaling up viral vector manufacturing: platformized adherent or suspension processes, DOE-guided parameter definition, scale-down models that reflect large-scale hydrodynamics, and purification trains tuned for target quality attributes.

‍

The payoff is substantial. DOE enables Andelyn’s teams to identify the design space, the parameter combination that maximizes the probability of process success, and to build the process around it. The result is a robust, high-yielding platform in which small-scale runs accurately represent large-scale manufacturing. And productivity is a quality indicator. When a process is highly efficient and high-yielding, downstream concentration steps become less aggressive, resulting in less co-concentration of host-cell DNA and host-cell proteins. High-yield processes also tend to arrive in the downstream with better full-to-empty capsid ratios already established, yielding dividends in both step recoveries and final product quality.

‍

Two Paths, One Framework

Not every program requires the same approach. Andelyn structures its platform around two primary development strategies. For rare diseases, orphan indications, and ocular programs, where patient populations are small and dosing windows can be narrow, the rapid path to GMP is the priority. This approach relies on an adherent platform with standardized parameters and serotype-agnostic ultracentrifugation. Scale-down is simple: it’s just a unit of operation. In one example, Andelyn has taken a program from plasmid to released clinical vector in under six months more than once.

‍

For large-scale programs where yield demands exceed roughly 6×10¹⁵ delivered vector genomes, suspension-based manufacturing with custom optimization is the answer. This pathway takes longer, typically about six months to reach toxicology material, but it enables runs up to 2,000 liters and provides the flexibility to run multiple batches at that scale if needed. Suspension cell cultures play a central role in viral vector scale up by enabling higher volumetric productivity, scalable mixing, and controlled oxygen transfer across bioreactor sizes, helping maintain comparability from development to GMP. They also support choosing the right production platform for viral vector scale up when dose needs and batch numbers are high.

‍

Choosing Platforms and Managing Challenges

How do you choose the right production platform for viral vector scale up? Start with dose and demand forecasting, serotype and producer-cell performance, required timelines, and facility capabilities. Adherent systems can speed early clinical entry with familiar unit ops; suspension systems offer greater scalability and consistency for larger programs. Common methods for scaling up viral vector manufacturing then include parameter scaling (P/V, kLa), single-use bioreactors, optimized transfection or infection strategies, and purification schemes aligned to quality targets.

‍

Scale-Down Is the Destination

What ties both strategies together is the role of the scale-down model. Rather than a retrospective add-on to satisfy a regulatory checkbox, Andelyn treats scale-down as a direct product of a well-executed scale-up. If the process has been properly characterized and optimized at every step, the scale-down model is already in place, providing the foundation for process characterization studies, PPQ batches, and ultimately a BLA filing. In gene therapy, the process is the product. At Andelyn, the process starts with optimization, and a clear, data-driven plan for viral vector scale up.

‍

Experience Andelyn’s Optimization-by-Design Framework

If you're interested in learning more about our design framework and platform process, please contact us.

Please click here to be taken to the external link

In AAV gene therapy manufacturing, speed is everything. Clinical timelines are unforgiving, patients can fall outside dosing windows, and the pressure to advance from early development to GMP production without stumbling at scale is immense. At Andelyn Biosciences, the answer to that pressure isn't to move faster; it's to move more smoothly. This perspective also shapes how we define viral vector scale-up: moving from small, development-scale runs to larger clinical and commercial batches while maintaining product quality, yield, and consistency. In short, viral vector scale-up means translating a well-characterized process across increasing volumes without compromising performance.

‍

"Fast is not always fast," says Andrew Moreo, Head of Process Development and Preclinical Manufacturing at Andelyn. "Smooth is always fast."

‍

That philosophy lies at the heart of what Andelyn calls Optimization-by-Design™, a systematic, data-driven approach to viral vector manufacturing that treats scale-down not as an afterthought but as a direct outcome of getting scale-up right from the start. Viral vector scale-up is challenging because vector-producing cells are sensitive to environmental shifts, shear, oxygen transfer, and nutrient gradients; upstream and downstream unit operations must be tightly controlled; and analytics must confirm comparability across scales. Raw material variability, full-to-empty ratios, and downstream recovery add further complexity.

‍

‍

Building for Scale from Day One

The question of scale must be asked before anything else. That includes: What does viral vector scale-up mean for this program’s dose, indication, and timeline? Which production platform and bioreactor configuration best support it?
"It’s one of the very first questions we ask," Moreo explains. "What scales do we need to be at? And ultimately, what does that scale-down look like at the end of the process?" The answer determines the entire development path and helps teams choose the right production platform for viral vector scale-up by weighing dose needs, serotype behavior, timeline constraints, and facility fit.

‍

DOE: The Engine Behind Optimization

At the center of Andelyn’s Curator® Platform is Design of Experiments (DOE), a multifactorial strategy that evaluates multiple process variables simultaneously rather than one at a time. Upstream, this means exploring cell growth parameters, dissolved oxygen, sparging, and bioreactor power input. Downstream, the same approach optimizes step recoveries across ultracentrifugation and all-column purification. These are among the common methods for scaling up viral vector manufacturing: platformized adherent or suspension processes, DOE-guided parameter definition, scale-down models that reflect large-scale hydrodynamics, and purification trains tuned for target quality attributes.

‍

The payoff is substantial. DOE enables Andelyn’s teams to identify the design space, the parameter combination that maximizes the probability of process success, and to build the process around it. The result is a robust, high-yielding platform in which small-scale runs accurately represent large-scale manufacturing. And productivity is a quality indicator. When a process is highly efficient and high-yielding, downstream concentration steps become less aggressive, resulting in less co-concentration of host-cell DNA and host-cell proteins. High-yield processes also tend to arrive in the downstream with better full-to-empty capsid ratios already established, yielding dividends in both step recoveries and final product quality.

‍

Two Paths, One Framework

Not every program requires the same approach. Andelyn structures its platform around two primary development strategies. For rare diseases, orphan indications, and ocular programs, where patient populations are small and dosing windows can be narrow, the rapid path to GMP is the priority. This approach relies on an adherent platform with standardized parameters and serotype-agnostic ultracentrifugation. Scale-down is simple: it’s just a unit of operation. In one example, Andelyn has taken a program from plasmid to released clinical vector in under six months more than once.

‍

For large-scale programs where yield demands exceed roughly 6×10¹⁵ delivered vector genomes, suspension-based manufacturing with custom optimization is the answer. This pathway takes longer, typically about six months to reach toxicology material, but it enables runs up to 2,000 liters and provides the flexibility to run multiple batches at that scale if needed. Suspension cell cultures play a central role in viral vector scale up by enabling higher volumetric productivity, scalable mixing, and controlled oxygen transfer across bioreactor sizes, helping maintain comparability from development to GMP. They also support choosing the right production platform for viral vector scale up when dose needs and batch numbers are high.

‍

Choosing Platforms and Managing Challenges

How do you choose the right production platform for viral vector scale up? Start with dose and demand forecasting, serotype and producer-cell performance, required timelines, and facility capabilities. Adherent systems can speed early clinical entry with familiar unit ops; suspension systems offer greater scalability and consistency for larger programs. Common methods for scaling up viral vector manufacturing then include parameter scaling (P/V, kLa), single-use bioreactors, optimized transfection or infection strategies, and purification schemes aligned to quality targets.

‍

Scale-Down Is the Destination

What ties both strategies together is the role of the scale-down model. Rather than a retrospective add-on to satisfy a regulatory checkbox, Andelyn treats scale-down as a direct product of a well-executed scale-up. If the process has been properly characterized and optimized at every step, the scale-down model is already in place, providing the foundation for process characterization studies, PPQ batches, and ultimately a BLA filing. In gene therapy, the process is the product. At Andelyn, the process starts with optimization, and a clear, data-driven plan for viral vector scale up.

‍

Experience Andelyn’s Optimization-by-Design Framework

If you're interested in learning more about our design framework and platform process, please contact us.

Please click here to be taken to the external linkDownload
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.